Citadel Advisors
LABU icon

Citadel Advisors’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Citadel Advisors’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.1M Buy
289,400
+27,135
+10% +$4.45M 0.01% 1403
2025
Q4 		$41.8M Sell
262,265
-190,220
-42% -$26.1M 0.01% 1584
2025
Q3 		$42.4M Buy
452,485
+175,435
+63% +$12.4M 0.01% 1559
2025
Q2 		$15.8M Buy
277,050
+98,300
+55% +$5.21M ﹤0.01% 2435
2025
Q1 		$10.9M Sell
178,750
-113,075
-39% -$9.63M ﹤0.01% 2740
2024
Q4 		$26.3M Buy
291,825
+29,655
+11% +$3.49M ﹤0.01% 1880
2024
Q3 		$33.8M Buy
262,170
+15,295
+6% +$2M 0.01% 1566
2024
Q2 		$28M Sell
246,875
-3,410
-1% -$365K 0.01% 1669
2024
Q1 		$33.2M Buy
250,285
+16,995
+7% +$2.22M 0.01% 1561
2023
Q4 		$28.5M Buy
233,290
+143,640
+160% +$11M 0.01% 1674
2023
Q3 		$6.83M Buy
89,650
+51,980
+138% +$5.33M ﹤0.01% 3196
2023
Q2 		$4.46M Buy
37,670
+4,035
+12% +$503K ﹤0.01% 3821
2023
Q1 		$3.3M Sell
33,635
-6,540
-16% -$887K ﹤0.01% 4487
2022
Q4 		$5.68M Buy
40,175
+7,695
+24% +$1.07M ﹤0.01% 3644
2022
Q3 		$4.55M Sell
32,480
-11,230
-26% -$2.06M ﹤0.01% 4032
2022
Q2 		$5.89M Buy
43,710
+2,310
+6% +$393K ﹤0.01% 3506
2022
Q1 		$13M Buy
41,400
+15,375
+59% +$5.8M ﹤0.01% 2559
2021
Q4 		$18.7M Buy
26,025
+355
+1% +$340K ﹤0.01% 2106
2021
Q3 		$28.4M Buy
25,670
+3,320
+15% +$4.08M 0.01% 1621
2021
Q2 		$32.9M Buy
22,350
+8,755
+64% +$12.1M 0.01% 1515
2021
Q1 		$21.5M Buy
13,595
+1,280
+10% +$3M 0.01% 1878
2020
Q4 		$24.7M Buy
12,315
+1,215
+11% +$1.94M 0.01% 1588
2020
Q3 		$11.9M Sell
11,100
-3,945
-26% -$4.52M ﹤0.01% 2090
2020
Q2 		$17.9M Buy
15,045
+3,610
+32% +$3.13M 0.01% 1604
2020
Q1 		$5.16M Buy
11,435
+4,125
+56% +$3.75M ﹤0.01% 2661
2019
Q4 		$8.41M Buy
7,310
+970
+15% +$870K ﹤0.01% 2410
2019
Q3 		$3.92M Sell
6,340
-3,255
-34% -$2.7M ﹤0.01% 3455
2019
Q2 		$9.63M Buy
9,595
+1,620
+20% +$1.57M ﹤0.01% 2221
2019
Q1 		$9.55M Sell
7,975
-3,465
-30% -$3.6M ﹤0.01% 2138
2018
Q4 		$7.52M Buy
11,440
+5,315
+87% +$5.57M ﹤0.01% 2235
2018
Q3 		$11.4M Buy
6,125
+2,405
+65% +$4.72M 0.01% 1955
2018
Q2 		$7.06M Buy
3,720
+755
+25% +$1.33M ﹤0.01% 2322
2018
Q1 		$4.71M Sell
2,965
-2,660
-47% -$4.95M ﹤0.01% 2529
2017
Q4 		$8.76M Buy
5,625
+3,490
+163% +$5.34M 0.01% 1862
2017
Q3 		$3.65M Buy
2,135
+180
+9% +$250K ﹤0.01% 2673
2017
Q2 		$2.46M Buy
1,955
+150
+8% +$151K ﹤0.01% 2896
2017
Q1 		$1.72M Buy
1,805
+490
+37% +$437K ﹤0.01% 3236
2016
Q4 		$823K Buy
1,315
+140
+12% +$105K ﹤0.01% 4137
2016
Q3 		$1.15M Buy
+1,175
New +$969K ﹤0.01% 3659

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors's LABU Position: Q4 2025 in Review

Citadel Advisors sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2025, closing a stake of 91,850 shares — an estimated $12.6M sold.

Citadel Advisors first reported a position in LABU in Q4 2015 and held it in 33 quarters. The position peaked at $14.4M in Q4 2022. 40 funds tracked by Wall St. Rank hold LABU as of Q4 2025.

  • Citadel Advisors reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 91,850 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2025, an estimated $12.6M.
  • Citadel Advisors first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2015 and held it in 33 quarters.
  • Citadel Advisors's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $14.4M in Q4 2022.
  • 40 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.